Lv2
110 积分 2023-10-12 加入
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
8个月前
已完结
The incidence of primary glomerulonephritis worldwide: a systematic review of the literature
9个月前
已完结
IgA nephropathy
9个月前
已完结
皖公网安备34019202002308
